Not sure which company would be more potentially profitable to go with? They have an upcoming PDUFA with a target action date of Feb 14, 2018. AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) is developing a drug called "Makena® subcutaneous auto-injector" which reduces the risk of preterm birth in pregnant women with a single baby. However Antares Pharma, Inc.(NASDAQ:ATRS) holds issued patents on the auto-injector device, which if "Makena® subcutaneous auto-injector" is approved, its said AMAG will request Orange Book listings of the eligible ATRS patents, the last one expiring in 2026. Take in mind the PDUFA filing is subject to a 10-month review. I'm just stuck between whether AMAG or ATRS is going to potentially make more on this PDUFA over this next 10 months, and in the development of this drug in general.